We are live on ! Find out more
BLRX

BioLineRX
BLRX

25 hedge funds and large institutions have $8.87M invested in BioLineRX in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

57% more capital invested

Capital invested by funds: $5.65M → $8.87M (+$3.22M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 24 → 25 (+1)

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
+$799K
2
VKH
Virtu KCG Holdings
New York
+$108K
3
Morgan Stanley
Morgan Stanley
New York
+$59.7K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$43.2K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$22.4K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$340K
2
Deutsche Bank
Deutsche Bank
Germany
-$26.6K
3
UBS Group
UBS Group
Switzerland
-$25K
4
ARTA
A.R.T. Advisors
New York
-$20K
5
TSS
Two Sigma Securities
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$5.11M +$799K +1,500 +25%
O
2
OrbiMed
New York
$1.19M – – –
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$733K +$22.4K +42 +4%
Morgan Stanley
4
Morgan Stanley
New York
$634K +$59.7K +112 +14%
OM
5
Opaleye Management
Massachusetts
$288K – – –
Deutsche Bank
6
Deutsche Bank
Germany
$245K -$26.6K -50 -12%
VKH
7
Virtu KCG Holdings
New York
$174K +$108K +203 +414%
MC
8
Menta Capital
California
$117K +$2.66K +5 +3%
NFG
9
Next Financial Group
Texas
$57K +$9.06K +17 +26%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$56K +$43.2K +81 New
BCA
11
Benchmark Capital Advisors
New York
$51K – – –
LTFS
12
Ladenburg Thalmann Financial Services
Florida
$46K – – –
CCB
13
Cutter & Co Brokerage
Missouri
$26K -$2.13K -4 -10%
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$26K – – –
Bank of New York Mellon
15
Bank of New York Mellon
New York
$21K +$533 +1 +3%
Bank of America
16
Bank of America
North Carolina
$19K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$19K +$14.4K +27 New
Wolverine Trading
18
Wolverine Trading
Illinois
$13K +$10.1K +19 New
Creative Planning
19
Creative Planning
Kansas
$12K -$4.26K -8 -32%
WSCM
20
Wellington Shields Capital Management
New York
$11K +$9.06K +17 New
UBS Group
21
UBS Group
Switzerland
$9K -$25K -47 -78%
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$4K – – –
KF
23
Krilogy Financial
Missouri
$1K – – –
Wells Fargo
24
Wells Fargo
California
$1K – – –
Millennium Management
25
Millennium Management
New York
– -$340K -708 Closed
1
2

BLRX Hedge Fund Activity: Q3 2016 in Review

25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2016, worth a combined $8.87M — up 57% from $5.65M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BLRX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Senvest Management, adding an estimated $799K. The largest seller was Millennium Management, exiting entirely with an estimated $340K sold.

  • 25 institutional investors held BioLineRX (BLRX) as of Q3 2016, up from 24 in Q2 2016.
  • Funds reported $8.87M of BioLineRX stock for Q3 2016, up 57% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q3 2016 and 3 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q3 2016 was Senvest Management, an estimated $799K added.
  • The largest BioLineRX seller in Q3 2016 was Millennium Management, an estimated $340K sold.

Based on aggregated 13F filings for Q3 2016.